GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Shiller PE Ratio
Switch to:

Biogen (MEX:BIIB) Shiller PE Ratio

: 12.64 (As of Today)
View and export this data going back to 2013. Start your Free Trial

As of today (2023-03-25), Biogen's current share price is MXN4991.71. Biogen's E10 for the quarter that ended in Dec. 2022 was MXN394.85. Biogen's Shiller PE Ratio for today is 12.64.

The historical rank and industry rank for Biogen's Shiller PE Ratio or its related term are showing as below:

MEX:BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.8   Med: 33.55   Max: 110.75
Current: 13.35

During the past years, Biogen's highest Shiller PE Ratio was 110.75. The lowest was 9.80. And the median was 33.55.

MEX:BIIB's Shiller PE Ratio is ranked better than
75.16% of 471 companies
in the Drug Manufacturers industry
Industry Median: 23.70 vs MEX:BIIB: 13.35

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Dec. 2022 was MXN74.340. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is MXN394.85 for the trailing ten years ended in Dec. 2022.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Shiller PE Ratio Historical Data

The historical data trend for Biogen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.45 21.24 15.16 13.53 13.69

Biogen Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.53 11.49 10.51 13.34 13.69

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Shiller PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls in comparison to its industry or sector. The grey bar indicates the Shiller PE Ratio's extreme value range as defined by GuruFocus.



Biogen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biogen's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=4991.71/394.85
=12.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's E10 for the quarter that ended in Dec. 2022 is calculated as:

For example, Biogen's adjusted earnings per share data for the three months ended in Dec. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=74.34/125.2218*125.2218
=74.340

Current CPI (Dec. 2022) = 125.2218.

Biogen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201303 22.375 98.209 28.529
201306 26.705 98.518 33.944
201309 26.763 98.790 33.924
201312 24.979 98.326 31.812
201403 26.650 99.695 33.474
201406 39.110 100.560 48.702
201409 47.918 100.428 59.748
201412 54.307 99.070 68.643
201503 53.179 99.621 66.845
201506 60.833 100.684 75.659
201509 69.881 100.392 87.165
201512 64.352 99.792 80.750
201603 78.102 100.470 97.343
201606 89.352 101.688 110.031
201609 90.637 101.861 111.424
201612 61.293 101.863 75.349
201703 66.709 102.862 81.210
201706 73.786 103.349 89.402
201709 103.239 104.136 124.144
201712 -27.039 104.011 -32.553
201803 102.989 105.290 122.486
201806 84.803 106.317 99.882
201809 135.844 106.507 159.714
201812 95.060 105.998 112.300
201903 137.596 107.251 160.652
201906 151.291 108.070 175.303
201909 163.999 108.329 189.572
201912 154.347 108.420 178.266
202003 180.818 108.902 207.916
202006 213.923 108.767 246.286
202009 96.609 109.815 110.163
202012 46.308 109.897 52.766
202103 55.817 111.754 62.543
202106 59.894 114.631 65.427
202109 44.502 115.734 48.150
202112 52.315 117.630 55.692
202203 42.321 121.301 43.689
202206 144.873 125.017 145.111
202209 157.340 125.227 157.334
202212 74.340 125.222 74.340

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (MEX:BIIB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biogen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines

Other Sources